A phase II study of high-dose medroxypro
β
Geoffrey Falkson; Hèndré C. Falkson
π
Article
π
1983
π
Springer
π
English
β 215 KB
Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high